Manufacturers pay $6.5 billion to healthcare providers in 2014

Manufacturers pay $6.5 billion to healthcare providers in 2014

The government released new data showing how much pharma and device companies spent for research and marketing purposes last year.

Fitbit IPO spurs questions about relevance to healthcare

The activity monitor dominates the fitness market, but competition in the overall health category is increasing.

Five things for pharma marketers to know: Monday, May 4

Five things for pharma marketers to know: Monday, May 4

Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways

Medtronic agrees to consent decree

The manufacturer's SynchroMed drug-infusion pump was associated with 14 deaths.

Editor's Desk: And the researchers go wild

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

FDA approves Boston Scientific atrial fibrillation device

The approval follows three advisory panel reviews and a complete response letter.

Device maker pays feds $2.8M over physician false claims

Device maker pays feds $2.8M over physician false claims

Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.

Philips focuses on healthcare tech

Lightbulb company Royal Philips is swapping its heritage for the consumer healthcare business.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

GE buys interest in DNA

The finance, electric and broadcasting company has taken a $1-billion interest in DNA technology.

Covidien buys firm armed with missile tech

Covidien is buying ingestible-camera company Given Imaging.

Report: J&J nearing hip settlement

The current number is reported to hover around $4 billion.

FDA exempts most mobile apps from scrutiny

FDA exempts most mobile apps from scrutiny

The agency issued final guidance on mobile apps, saying it will focus only on a subset that present the greatest risk to patients if they don't work correctly.

"Sensor you swallow" passes psych test

"Sensor you swallow" passes psych test

Proteus Digital Health's ingestible sensor shows utility as an adherence tool for those on psych meds, a study suggests.

Mayo device helps monitor heart patients from afar

Device maker Preventice says the peel-and-stick monitor has the potential to go beyond the critical care market and into the sports world.

J&J consolidates, rebrands Ethicon units

J&J consolidates, rebrands Ethicon units

Driven by consolidation in the healthcare industry, J&J is reuniting Ethicon, Inc. and Ethicon Endo-Surgery to present surgeons and health systems with a single face.

Abbott closes Q1 with sales boost

The company expects emerging markets to rise in importance and says it's scoping out possible device acquisitions.

Senate vote puts ACA's device tax in doubt

Senate vote puts ACA's device tax in doubt

In a big win for the device industry, Senators voted overwhelmingly on a symbolic— but politically potent—motion to scrap the 2.3% device excise tax.

WebMD digs deeper into the everyday

WebMD digs deeper into the everyday

A deal with QualcommLife aims to fuse WebMD content with a suite of disease state management tools.

Growth in devices, online video to drive media this year, buyers say

What changes in marketing or audience viewing habits might impact pharma's media investment this year? Media buyers weigh in on the hot channel trends.

DePuy coaches joint pain sufferers not to delay surgery

DePuy coaches joint pain sufferers not to delay surgery

A new campaign from J&J's DePuy Orthopedics, aimed at raising awareness of joint replacement, features Baby Boomers' letters to their younger selves.

Baxter to buy hemodialysis giant Gambro AB for $4 billion

Baxter to buy hemodialysis giant Gambro AB for $4 billion

After almost a year of negotiations, Baxter has reached a $4 billion deal for Swedish firm Gambro AB as it makes a play for the kidney dialysis market.

Company news: MedMira; FDA device ID

Diagnostics firm MedMira gets a contract from the US Army to develop a screening tool, and the FDA proposes some new device guidelines.

Endo rebrands to move beyond roots in pain drugs

Endo rebrands to move beyond roots in pain drugs

Endo is restructuring, bringing its four operating units under the same corporate roof and rebranding to reflect its diversification out of its origins in pain and urology drugs.

Sanofi contest gooses diabetes tech innovation

Sanofi contest gooses diabetes tech innovation

Sanofi is re-upping its social media-driven Data Design Diabetes Innovation Challenge contest, which last year kicked up a wealth of innovative ideas and buzz for the price of $200,000 in prize money and a few salaries.

FDA to IOM: More work? No thanks

The FDA is moving cautiously on a call by the Institute of Medicine to scrap the approvals process for many medical devices.

FDA guidance exempts most pharma apps from scrutiny

FDA guidance exempts most pharma apps from scrutiny

FDA issued draft guidance on mobile medical apps, focusing narrowly on those programs that augment regulated medical devices or turn mobile devices into medical devices.

Mobile pill cap takes social approach to raising compliance

Mobile pill cap takes social approach to raising compliance

A company that markets a pill cap with a built-in cellular connection puts a social twist on getting patients to take their meds.

Insulin pen makers roll out new promos

Insulin pen makers roll out new promos

Sanofi-Aventis US is rolling out a consumer campaign for its Lantus SoloStar pen aimed at getting people with type 2 diabetes to think differently about insulin, while Novo Nordisk revs up another racing-themed social media effort for its FlexPen.

Bayer glucose meter aimed at gamers

Bayer glucose meter aimed at gamers

Bayer Diabetes Care partnered with Nintendo on a glucose meter for kids that incorporates gaming.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.